Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Re: 10-q ....
5
Jan 18, 2011 11:23AM
4
Jan 18, 2011 11:38AM

Jan 18, 2011 12:11PM
4
Jan 18, 2011 01:37PM
1
Jan 18, 2011 02:06PM

<Should not such "license revenues" be sufficient to provide funds for TPL/Alliacense to be able to pay back their GD loans/advances?>

Well I'm not so sure it is as obvious as you make it to be. Money coming into PDS is for recapitalization of PDS. Until such time as there is a distribution available to be made to the JV partners, there may not be any money for PDS to apply against the loan.

As to why PDS made the loan? Probably not a bad question to ask.

IMO, the court is probably exerting some control over the partnership until things get resolved. It certainly appears that the accounts payable to TPL keeps increasing over the past 2 quarters. The court may only have blessed certain reimbursements to Alliacense. So yes, TPL owes PDS some .4 mil., but it appears that PDS owes TPL much more. I believe over 3 mil. Corrections welcomed.

Opty


Jan 18, 2011 02:40PM
3
Jan 18, 2011 03:11PM

Jan 18, 2011 04:40PM

Jan 18, 2011 04:43PM
Share
New Message
Please login to post a reply